UCB, a global biopharmaceutical company, has recently presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for bimekizumab in PsO and will reinforce physicians’ positive opinions about the drug, according to GlobalData, a leading data and analytics company. Leia Mais »

Marisa Lima, especialista em saúde e CEO da Doutor Cuidados, explica o que muda com essa autorização Leia Mais »